<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) comprise a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of clonal hematopoietic stem cell disorders characterized by <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, ineffective hematopoiesis leading to peripheral blood cytopenias, and a variable risk of leukemic progression </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> primarily affects the elderly, and although its prevalence is increasing, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is frequently overlooked and underdiagnosed </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> should be suspected in any patient with unexplained cytopenias, and a bone marrow evaluation is ultimately needed to make the diagnosis and exclude other causes of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The last 15 years have witnessed significant advances in our understanding of the complex pathogenesis, classification and prognostication, and therapeutic approaches to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Several prognostic models facilitate outcome prediction and risk-adapted therapy </plain></SENT>
<SENT sid="5" pm="."><plain>The addition of <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, <z:chebi fb="0" ids="50131">decitabine</z:chebi>, and lenalidomide to erythropoiesis-stimulating agents in our armamentarium offered new effective therapeutic options for many patients who are not candidates for intensive interventions </plain></SENT>
<SENT sid="6" pm="."><plain>Improved understanding of the genetic, epigenetic, and immunologic mechanisms that operate in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> will help develop better prognostication tools and rationally design more effective therapies </plain></SENT>
<SENT sid="7" pm="."><plain>Hospitalists are likely to encounter both patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and patients in whom <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> should be suspected </plain></SENT>
<SENT sid="8" pm="."><plain>In this review of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we focus on the epidemiology, diagnosis, pathogenesis, classification and prognostic tools, and treatment options </plain></SENT>
<SENT sid="9" pm="."><plain>Journal of Hospital Medicine 2013;8:351-357. Â© 2013 Society of Hospital Medicine </plain></SENT>
</text></document>